Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a combination product containing lansoprazole, amoxicillin, and clarithromycin. Lansoprazole is a proton pump inhibitor (PPI) that reduces stomach acid production. Amoxicillin and clarithromycin are antibiotics used to eradicate *Helicobacter pylori* (H. pylori) infection.
## Primary Indications
* Treatment of *Helicobacter pylori* infection in patients with peptic ulcer disease.
## Adult Dosing
* **Sompraz HP:** One dose pack should be taken twice daily for 10 days. Each dose pack contains:
* Lansoprazole 30 mg capsules
* Amoxicillin 500 mg capsules
* Clarithromycin 250 mg tablets
## Pediatric Dosing
* Pediatric dosing for Sompraz HP is not established. Dosing of individual components may be considered based on weight and clinical judgment.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustment for lansoprazole, amoxicillin, or clarithromycin in mild to moderate renal impairment is typically recommended. However, caution and potential dose reduction of amoxicillin may be considered in severe renal impairment.
* **Hepatic Impairment:** No specific dose adjustment for lansoprazole is typically recommended. Dose reduction may be considered for clarithromycin in patients with hepatic impairment.
## Contraindications
* Hypersensitivity to lansoprazole, amoxicillin, clarithromycin, other macrolides, or penicillins.
* History of hypersensitivity to penicillin or cephalosporin antibiotics.
* Concomitant use with cisapride, ergot alkaloids, midazolam, pimozide, or other drugs that are highly metabolized by CYP3A4 and can prolong the QT interval.
* History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, abdominal pain, headache, taste disturbance.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), severe allergic reactions (anaphylaxis), Stevens-Johnson syndrome, toxic epidermal necrolysis, QT prolongation, hepatotoxicity, *H. pylori* resistance.
## Key Drug Interactions
* **Lansoprazole:** May decrease the absorption of drugs requiring an acidic gastric pH (e.g., ketoconazole, itraconazole, digoxin). May increase the absorption of drugs that are degraded in acidic environments. Potential for interaction with drugs metabolized by CYP2C19 and CYP3A4.
* **Clarithromycin:** Potent inhibitor of CYP3A4. Significant interactions with numerous drugs including statins, warfarin, theophylline, carbamazepine, certain calcium channel blockers, certain antiretrovirals, and many others. Coadministration with colchicine can be fatal.
* **Amoxicillin:** May decrease the effectiveness of oral contraceptives. May interact with methotrexate and allopurinol.
## Monitoring
* Monitor for signs and symptoms of hypersensitivity reactions.
* Monitor for signs and symptoms of *C. difficile*-associated diarrhea.
* Evaluate for improvement of ulcer symptoms.
* Assess for adherence and completion of the full 10-day course.
* Consider repeat testing for *H. pylori* eradication after treatment completion if indicated.
## Clinical Pearls
* This combination is a standard regimen for *H. pylori* eradication.
* Ensure patients complete the full 10-day course of therapy to maximize eradication rates and minimize resistance.
* Advise patients to take the medication as directed, usually twice daily before a meal.
* Educate patients on potential adverse effects, especially diarrhea, and to report severe or persistent symptoms.
* Be aware of significant drug-drug interactions, particularly with clarithromycin.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Drug information can change, and it is the responsibility of the prescriber to verify the accuracy and completeness of the information prior to use.
